Catherine Eckford

The ABPI asserts that its recommendations will help generate confidence in the regulation of medicines in the UK.

This investment supports AstraZeneca’s strategy to drive the biopharmaceutical company's development in the US.

The deal will help AbbVie to strengthen its neuroscience pipeline, including aiding development of therapies for delivery into the CNS.

Preliminary results from an ongoing trial of a novel biologic have confirmed favourable efficacy and safety in a malignant lung cancer.

Authorisation in Great Britain means eligible patients can access the treatment, which is part of a new class of amyloid targeting therapies.

The new regulation could become lawful in the UK next year, according to the Medicines and Healthcare products Regulatory Agency (MHRA).

The study offers promising data on strengthening borosilicate glass vials using ion-exchange, considering the limited research in this area.

More than half of the multiple myeloma patients included in this study would have been ineligible for the CARTITUDE-1 trial, research reports.

The new facility will aid global supply of the first FDA-approved intravesical non-replicating gene therapy for adults with a common cancer.

The research “clearly demonstrates" the benefits industry clinical trials have on the UK economy, says APBI Chief Exec about the report.